Genomic Health Target of Unusually High Options Trading (GHDX)

Genomic Health, Inc. (NASDAQ:GHDX) was the target of unusually large options trading activity on Tuesday. Investors purchased 1,015 call options on the stock. This represents an increase of approximately 1,310% compared to the typical daily volume of 72 call options.

Several equities research analysts have recently issued reports on GHDX shares. William Blair downgraded shares of Genomic Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, December 20th. ValuEngine upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Friday, December 15th. Barclays reiterated a “sell” rating and set a $28.00 price target on shares of Genomic Health in a research note on Monday, January 8th. BidaskClub upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Tuesday, December 19th. Finally, Zacks Investment Research downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $32.33.

Shares of Genomic Health (NASDAQ GHDX) opened at $32.45 on Wednesday. Genomic Health has a 52 week low of $26.54 and a 52 week high of $37.50. The firm has a market cap of $1,144.78, a price-to-earnings ratio of -270.42 and a beta of 0.59.

In other news, insider James J. Vaughn sold 3,004 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $34.09, for a total value of $102,406.36. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $29.94, for a total transaction of $149,700.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 79,338 shares of company stock worth $2,635,251. 46.20% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Genomic Health by 6.8% during the second quarter. Vanguard Group Inc. now owns 1,670,622 shares of the medical research company’s stock worth $54,379,000 after buying an additional 106,452 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Genomic Health by 16.2% during the fourth quarter. Renaissance Technologies LLC now owns 1,012,000 shares of the medical research company’s stock worth $34,610,000 after buying an additional 141,300 shares in the last quarter. State Street Corp boosted its stake in Genomic Health by 2.5% during the second quarter. State Street Corp now owns 517,313 shares of the medical research company’s stock worth $16,840,000 after buying an additional 12,696 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Genomic Health by 1.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 503,244 shares of the medical research company’s stock worth $16,150,000 after buying an additional 5,904 shares in the last quarter. Finally, State Farm Mutual Automobile Insurance Co. boosted its stake in Genomic Health by 10.6% during the fourth quarter. State Farm Mutual Automobile Insurance Co. now owns 350,741 shares of the medical research company’s stock worth $11,995,000 after buying an additional 33,501 shares in the last quarter. Hedge funds and other institutional investors own 90.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/21/genomic-health-target-of-unusually-high-options-trading-ghdx.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply